首页> 外文期刊>Journal of population therapeutics and clinical pharmacology >NOVEL MEASURES OF BENZODIAZEPINE & Z-DRUG UTILISATION TRENDS IN A CANADIAN PROVINCIAL ADULT POPULATION (2001-2016 )
【24h】

NOVEL MEASURES OF BENZODIAZEPINE & Z-DRUG UTILISATION TRENDS IN A CANADIAN PROVINCIAL ADULT POPULATION (2001-2016 )

机译:加拿大省成年人口中苯并二氮杂Z和Z-药物利用趋势的新措施(2001-2016)

获取原文
           

摘要

Purpose (1) To evaluate trends for benzodiazepines (BZD) and Z-Drugs over 15-years in a general Canadian adult population measured by: (a) consumption (b) pharmacologic exposure (c) dose intensity, and (d) prevalence of use. (2) To demonstrate the utility of Diazepam Milligram Equivalents (DME) based measurements when used in conjunction with traditional standard measurements of drug utilization. Methods Administrative data covering all prescriptions from April 2001-March 2016 for BZD and Z-Drugs for patients ≥18 years was used. Consumption was calculated as DDD/1000-person days. Dose intensity (DI) was determined by conversion of individual daily doses to DME. Pharmacologic exposure (PE) was calculated as DME-DDD/1000 person days. Prevalence was determined as the proportion of the adult population with receipt of ≥1 prescription in a given year. Changes were assessed using either Poisson or simple linear regression at an alpha of 0.05. Results Z-Drug usage (~99% zopiclone) statistically increased on every measure over the course of the study period; consumption (8.2 to 28.6 DDD/1000-person days), PE (4.1 to 14.3 DME-DDD/1000-person days), DI (5.0 to 5.43 DME/day) and prevalence (2.0% to 4.8%). For BZD the only statistically significant changes were in DI (17.1 to 20.1 DME/day) and prevalence (9.3% to 8.1%). Consumption and PE gradually increased from 2001 to 2011 for BZD before declining thus producing a non-significant trend for BZD. Conclusion (1) Z-Drug usage increased markedly from 2001 to 2016 whereas BZD use only increased in terms of DI. (2) DME-based measurements enable further interpretation of BZD utilization compared to sole reliance on DDD.
机译:目的(1)通过以下方法评估加拿大普通成年人中15年间苯二氮卓类药物(BZD)和Z-药物的趋势:(a)食用(b)药物暴露(c)剂量强度,以及(d)患病率使用。 (2)证明当与传统的药物利用率标准测量结合使用时,基于地西p毫克当量(DME)的测量的实用性。方法使用行政数据,涵盖从2001年4月至2016年3月所有BZD和Z-Drugs≥18岁患者的所有处方。消费量按DDD / 1000人日计算。剂量强度(DI)通过将单个日剂量转换为DME来确定。药理暴露(PE)计算为DME-DDD / 1000人日。患病率确定为在给定年份中接受≥1个处方的成年人口比例。使用泊松或简单线性回归以α为0.05评估变化。结果在整个研究过程中,每种措施的Z药物使用量(〜99%佐匹克隆)均在统计上有所增加;消费(8.2至28.6 DDD / 1000人日),PE(4.1至14.3 DME-DDD / 1000人日),DI(5.0至5.43 DME /日)和患病率(2.0%至4.8%)。对于BZD,仅有的统计上显着变化是DI(17.1至20.1 DME /天)和患病率(9.3%至8.1%)。从2001年到2011年,BZD的消费量和PE逐渐增加,然后下降,因此对BZD的影响不显着。结论(1)从2001年到2016年,Z-Drug的使用量显着增加,而BZD的使用仅以DI量增加。 (2)与仅依赖DDD相比,基于DME的测量可以进一步解释BZD利用率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号